RxDoctor Payments Data

Gregory Trolley, MD

Neurology · Houston, TXNPI 1609019652

Payments from drug & device makers

$6,967in general payments, 2019–2025

Across 389 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$726
  • AbbVie$658
  • Novartis$590
  • Lundbeck LLC$498
  • UCB, Inc.$392
  • Lilly USA, LLC$378
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$6,953100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,967 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$222,911
Medicare patients
1,026
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab24$1,255,619
AustedoDeutetrabenazine38$274,707
Tascenso OdtFingolimod Lauryl Sulfate11$115,234
QuliptaAtogepant91$108,946
Aimovig AutoinjectorErenumab-Aooe70$86,839
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$65,004
Nurtec OdtRimegepant Sulfate38$42,944
Memantine Hcl1,370$42,894
BotoxOnabotulinumtoxina30$36,137
NamzaricMemantine Hcl/Donepezil Hcl41$32,796
Emgality PenGalcanezumab-Gnlm23$27,345
Carbidopa-LevodopaCarbidopa/Levodopa813$22,247
Gabapentin806$21,633
Levetiracetam693$20,874
Lacosamide159$19,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$108$1,255,61924 claims
Teva Pharmaceuticals USA, Inc.Austedo$335$274,70738 claims
AbbVieQulipta, Botox, Namzaric, Ubrelvy$658$192,147176 claims
Cycle Pharmaceuticals IncTascenso Odt$27$115,23411 claims
Grifols USA, LLCGamunex-C$27$65,00415 claims
PfizerNurtec Odt$726$42,94438 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Rytary$27$21,083132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →